In 2016, IRSA applied to MSAC to restore public funding for a selected patient group likely to benefit from early vertebroplasty. The application was based on the VAPOUR trial. We are pleased to announce MSAC has supported the application for the patient subgroup in the VAPOUR trial who showed greatest benefit from vertebroplasty. The decision is published on the MSAC website as a Public Summary Document (PSD).
Admin2020-08-18T09:43:26+10:00Public Summary Document Application No. 1466 – DecisionAdmin2020-08-18T09:43:26+10:00